Citations

Clear

4847 citation(s) found for "Tu, Eric".

Immunopathogenesis of olmesartan‐associated enteropathy
Marietta, Eric, Nadeau, Ashley, Cartee, Amanda K. , Singh, I., Rishi, Abdul , Choung, Rok Seon , Wu, T.‐T., Rubio‐Tapia, Alberto , Murray, Joseph A. , Choung, Rok Seon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 1, 2015 | Volume: 42 | Issue: 11-12 | Pages: 1303-1314

10.1111/apt.13413 | PMID 26423313 Get It

SummaryBackgroundOlmesartan‐associated enteropathy (OAE) is characterised by diarrhoea, nausea, vomiting, abdominal pain, weight loss and severe sprue‐like enteropathy, all of which are resolved after discontinuation of olmesartan medoximil.AimTo determine the mechanistic similarities of OAE with coeliac sprue.MethodsDuodenal biopsies were extracted from OAE patients before (n = 11) or after (n = 17) discontinuation of olmesartan medoxomil (on or off olmesartan medoxomil). There were seven ‘on/off’ paired samples. Formalin‐fixed biopsies were stained for CD8, CD4, FoxP3, IL‐15R and psmad 2/3. Caco2 cells (human colonic epithelial line) were treated with olmesartan medoxomil and stained for IL‐15, IL‐15R and ZO‐1.ResultsIn the ‘on olmesartan medoxomil’ duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T‐cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil. IL15R expression is also increased with olmesartan medoxomil use. Evaluation of the effect of olmesartan medoxomil upon Caco‐2 cells demonstrated that IL15 expression is increased in response to olmesartan medoxomil treatment. Further, ZO‐1, a tight junction protein, is disrupted in olmesartan medoxomil‐treated Caco‐2 cells.ConclusionsOlmesartan‐associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients.
Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults
Jones, Amy, Flanagan, Eoin P. , Pittock, Sean J. , Mandrekar, Jay , Eggers, Scott D.Z. , Ahlskog, J. Eric , McKeon, Andrew , Jones, Amy L., Mandrekar, Jay N., Eggers, Scott D, Pittock, S J , Flanagan, E P , McKeon, Andrew

Mayo Clinic

JAMA Neurology | September 28, 2015 | Volume: 72 | Issue: 11 | Pages: 1304

10.1001/jamaneurol.2015.2378 | PMID 26414229 Get It

Clinical Characteristics of Sarcoid Arthropathy: A Population‐Based Study
Ungprasert, Patompong , Crowson, Cynthia S. , Matteson, Eric L.

Mayo Clinic

Arthritis Care & Research | September 28, 2015 | Volume: 68 | Issue: 5 | Pages: 695-699

10.1002/acr.22737 | PMID 26415117 Get It

ObjectiveThe epidemiology and clinical characteristics of sarcoid arthropathy are not well described, as only referral‐based studies have been reported. This study aimed to use the data from a geographically well‐defined population to characterize the clinical characteristics of sarcoid arthropathy.MethodsAn inception cohort of patients with incident sarcoidosis in the years 1976–2013 in a geographically well‐defined population was identified based on comprehensive individual medical records review. Inclusion required physician diagnosis supported by histopathology and radiologic features of intrathoracic sarcoidosis, compatible clinical presentation, and exclusion of other granulomatous diseases. Patients with joint pain were then identified from this cohort.ResultsIn 1976–2013, all 345 incident cases of sarcoidosis were identified. Symptoms of joint pain occurred in 42 patients (mean age 41.2 years, 57.1% female, and 95% white), and 35 patients had swollen joint(s) on physical examination. Most patients had arthralgia prior to the diagnosis of sarcoidosis, with an average time to diagnosis of 21 days. Of the 35 cases, oligoarthritis (2 to 4 joints) was the most common pattern (88% of cases), followed by monoarthritis (6%) and polyarthritis (6%). Ankles were involved in 91% of cases. In the majority of patients (88%), the arthritis resolved within 6 weeks. Classic Lofgren's syndrome was observed in 11 patients (26%).ConclusionInflammatory arthritis occurs in a minority of patients with sarcoidosis. Acute oligoarthritis with bilateral ankle involvement was the most common pattern of sarcoid arthropathy. It should be noted that the generalizability of the results may be limited, as the cohort was predominantly white.
Ligament Tissue Engineering Using a Novel Porous Polycaprolactone Fumarate Scaffold and Adipose Tissue-Derived Mesenchymal Stem Cells Grown in Platelet Lysate
Wagner, Eric R. , Bravo, Dalibel , Dadsetan, Mahrokh, Riester, Scott M. , Chase, Steven C. , Dietz, Allan B. , Wijnen, André J. van , Yaszemski, Michael J. , Chase, Steven, van Wijnen, Andre J, Westendorf, Jennifer J. , Kakar, Sanjeev , van Wijnen, Andre J , Dietz, Allan B , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | September 28, 2015 | Volume: 21 | Issue: 21-22 | Pages: 2703-2713

10.1089/ten.tea.2015.0183 | PMID 26413793 Get It

Classification of current anticancer immunotherapies
Galluzzi, Lorenzo , Vacchelli, Erika , Pedro, José Manuel Bravo‐San , Buqué, Aitziber , Senovilla, Laura , Baracco, Elisa Elena, Bloy, Norma , Castoldi, Francesca , Abastado, Jean-Pierre, Agostinis, Patrizia , Apte, Ron N., Aranda, Fernando , Ayyoub, Maha , Beckhove, Philipp , Blay, Jean‐Yves , Bracci, Laura , Caignard, Anne , Cavallo, Federica , Celis, Estaban, Clayton, Aled , Coussens, Lisa M. , Dhodapkar, Madhav V. , Eggermont, Alexander , Fearon, Douglas T. , Fučíková, Jitka , Galon, Jérôme , Garg, Abhishek D. , Ghiringhelli, François , Gilboa, Eli , Gnjatic, Sacha , Hoos, Axel , Jäger, Dirk, Kaliński, Paweł , Kärre, Klas , Kepp, Oliver , Kiessling, Rolf , Klein, Eva, Knuth, Alexander, Lewis, Claire E. , Lugli, Enrico , Mach, J P, Mattei, Fabrizio , Mavilio, Domenico , Melero, Ignacio , Melief, Cornelis J.M., Moretta, Lorenzo , Odunsi, Adekunke, Palucka, A. Karolina, Porgador, Angel , Prendergast, George C. , Restifo, Nicholas P. , Rizvi, Naiyer A. , Schreiber, Hans , Seliger, Barbara , Shiku, Hiroshi , Špíšek, Radek , Srivastava, Pramod K. , Vile, Richard G. , Wagner, Hermann, Weber, Jeffrey S. , Zitvogel, Laurence , Zou, Weiping , Abastado, Jean‐Pierre, Castelli, Chiara , Cerundolo, Vincenzo , Colombo, Mario P. , Fridman, Wolf H. , Gabrilovich, Dmitry I. , Giaccone, Giuseppe , Hosmalin, Anne , Kirkwood, John M. , Liblau, Roland , Lotze, Michael T. , Mittendorf, EA , Okada, Hideho , Peter, Marcus E. , Pienta, Kenneth J , Rabinovich, Gabriel A , Sautès‐Fridman, Catherine , Silva‐Santos, Bruno , Smyth, Mark J. , Speiser, Daniel E. , Talmadge, James E. , Tartour, Éric , Burg, Sjoerd H. van der , Eynde, Benoı̂t J. Van den , Whiteside, Theresa L , Wolchok, Jedd D. , Kroemer, Guido , Gnjatic, Sacha , Blay, Jean-Yves , Galon, Jerome , Weber, Jeffrey

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 5 | Issue: 24 | Pages: 12472-12508

10.18632/oncotarget.2998 | PMID 25537519 Get It

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT‐AF)
Kim, Sunghee , Thomas, Laine , Fonarow, Gregg C. , Holmqvist, Fredrik , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Chang, Paul, Piccini, Jonathan P. , Patients, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and, Steinberg, Benjamin A. , Gersh, Bernard J. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Patients, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and

Mayo Clinic

Journal of the American Heart Association | September 15, 2015 | Volume: 4 | Issue: 9 | Pages: No page available

10.1161/jaha.115.002031 | PMID 26370445 Get It

Background Most patients with atrial fibrillation ( AF ) require rate control; however, the optimal target heart rate remains under debate. We aimed to assess rate control and subsequent outcomes among patients with permanent AF . Methods and Results We studied 2812 US outpatients with permanent AF in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. Resting heart rate was measured longitudinally and used as a time‐dependent covariate in multivariable Cox models of all‐cause and cause‐specific mortality during a median follow‐up of 24 months. At baseline, 7.4% (n=207) had resting heart rate <60 beats per minute (bpm), 62% (n=1755) 60 to 79 bpm, 29% (n=817) 80 to 109 bpm, and 1.2% (n=33) ≥110 bpm. Groups did not differ by age, previous cerebrovascular disease, heart failure status, CHA 2 DS 2 ‐ VAS c scores, renal function, or left ventricular function. There were significant differences in race ( P =0.001), sinus node dysfunction ( P =0.004), and treatment with calcium‐channel blockers ( P =0.006) and anticoagulation ( P =0.009). In analyses of continuous heart rates, lower heart rate ≤65 bpm was associated with higher all‐cause mortality (adjusted hazard ratio [ HR ], 1.15 per 5‐bpm decrease; 95% CI , 1.01 to 1.32; P =0.04). Similarly, increasing heart rate >65 bpm was associated with higher all‐cause mortality (adjusted HR , 1.10 per 5‐bpm increase; 95% CI , 1.05 to 1.15; P <0.0001). This relationship was consistent across endpoints and in a broader sensitivity analysis of permanent and nonpermanent AF patients. Conclusions Among patients with permanent AF , there is a J‐shaped relationship between heart rate and mortality. These data support current guideline recommendations, and clinical trials are warranted to determine optimal rate control. Clinical Trial Registration URL : http://clinicaltrials.gov/ . Unique identifier: NCT01165710.
Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals
Reitz, Christiane , Cheng, Rong , Jun, Gyungah , Sato, Christine , Rajbhandary, Ruchita, Wang, Li San, Lin, Chiao‐Feng , Larson, Eric B., Graff‐Radford, Neill R. , Evans, Denis A., Jager, Philip L. De , Crane, Paul K. , Buxbaum, Joseph D. , Murrell, Jill R. , Raj, Towfique , Ertekin‐Taner, Nilüfer , Logue, Mark, Baldwin, Clinton T., Green, Robert C. , Barnes, Lisa L. , Cantwell, Laura B., Fallin, M. Daniele , Go, Rodney C.P., Griffith, Patrick , Obisesan, Thomas O. , Bennett, David A. , Hendrie, Hugh C. , Hall, Kathleen, Byrd, Goldie S. , Kukull, Walter A. , Foroud, Tatiana M., Haines, Jonathan L. , Farrer, Lindsay A. , Pericak‐Vance, Margaret A. , Schellenberg, Gerard D. , Mayeux, Richard , Morris, John C. , Leverenz, James B. , DeKosky, Steven T. , Håkonarson, Håkon , Jarvik, Gail P. , Albin, Roger L. , Lyketsos, Constantine G. , Jicha, Gregory A. , Demirci, F. Yesim , Burke, James R. , Cao, Chuanhai , Carroll, Steven L. , Cribbs, David H. , Mack, Wendy J. , Sonnen, Joshua A. , Bennett, David A. , Ghani, Mahdi , Vardarajan, Badri Narayan , Naj, Adam Christian , Valladares, Otto , Manly, Jennifer J. , Lunetta, Kathryn L. , Kamboh, M. Ilyas , López, Oscar L. , Goate, Alison , Lee, Joseph H. , George‐Hyslop, Peter St , Rogaeva, Ekaterina A. , Hakonarson, Hakon , Leverenz, James B , Jarvik, Gail P , Morris, John C , Jicha, Gregory A , Sonnen, Joshua , Barnes, Lisa L

Mayo Clinic

JAMA Neurology | September 14, 2015 | Volume: 72 | Issue: 11 | Pages: 1313

10.1001/jamaneurol.2015.1700 | PMID 26366463 Get It

2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative
Dejaco, Christian , Singh, Yogesh Preet , Perel, Pablo , Hutchings, Andrew , Camellino, Dario , Mackie, Sarah , Abril, Andy , Bachta, Artur , Bálint, Péter, Barraclough, Kevin, Bianconi, L., Buttgereit, Frank , Carsons, Steven E. , Ching, Daniel , Cid, María C. , Cimmino, Marco A. , Diamantopoulos, Andreas P. , Docken, William P., Duftner, Christina , Fashanu, Billy, Gilbert, Kate, Hildreth, Pamela, Hollywood, Jane, Jayne, David , Lima, Manuella , Maharaj, Ajesh B. , Mallen, Christian , Martínez‐Taboada, Víctor M. , Maz, Mehrdad , Merry, Steven, Miller, Jean , Mori, Shunsuke , Nordborg, Elisabeth, Nott, Jennifer, Padbury, Hannah, Pease, Colin, Salvarani, Carlo , Schirmer, Michael , Schmidt, Wolfgang , Tronnier, David, Wagner, Alexandre, Whitlock, Madeline, Matteson, Eric L. , Merry, Stephen , Souza, Alexandre Wagner Silva de , Neill, Lorna M. , Salvarani, Carlo , Spiera, Robert , Wagner, Alexandre, Dasgupta, Bhaskar , Dejaco, Christian , Merry, Stephen P , Mackie, Sarah Louise , Jayne, David , Buttgereit, Frank , Singh, Yogesh Preet , de Souza, Alexandre Wagner Silva

Mayo Clinic

Arthritis & Rheumatology | September 10, 2015 | Volume: 67 | Issue: 10 | Pages: 2569-2580

10.1002/art.39333 | PMID 26352874 Get It

Abstract Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients’ and clinicians’ values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow‐up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti‐rheumatic drugs (DMARDs), as well as the roles of non‐steroidal anti‐rheumatic drugs and non‐pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.
Desiderata for computable representations of electronic health records-driven phenotype algorithms
Mo, Huan , Thompson, William K. , Rasmussen, Luke V. , Pacheco, Jennifer A. , Jiang, Guoqian , Kiefer, Richard C. , Zhu, Qian , Xu, Jie , Montague, Enid , Mentch, Frank , Ni, Yizhao , Wehbe, Firas , Peissig, Peggy , Tromp, Gerard , Larson, Eric B. , Pathak, Jyotishman , Denny, Joshua C. , Speltz, Peter, Jarvik, Gail P. , Bejan, Cosmin A, Borthwick, Kenneth M., Kitchner, Terrie, Roden, Dan M. , Bejan, Cosmin A. , Kiefer, Richard, Carrell, David , Lingren, Todd , Chute, Christopher G. , Kho, Abel , Bejan, Cosmin A, Williams, Marc S , Roden, Dan M. , Harris, Paul A. , Denny, Joshua C , Jarvik, Gail P , Rasmussen, Luke V , Pacheco, Jennifer A

Mayo Clinic

Journal of the American Medical Informatics Association | September 6, 2015 | Volume: 22 | Issue: 6 | Pages: 1220-1230

10.1093/jamia/ocv112 | PMID 26342218 Get It

AbstractBackground Electronic health records (EHRs) are increasingly used for clinical and translational research through the creation of phenotype algorithms. Currently, phenotype algorithms are most commonly represented as noncomputable descriptive documents and knowledge artifacts that detail the protocols for querying diagnoses, symptoms, procedures, medications, and/or text-driven medical concepts, and are primarily meant for human comprehension. We present desiderata for developing a computable phenotype representation model (PheRM).Methods A team of clinicians and informaticians reviewed common features for multisite phenotype algorithms published in PheKB.org and existing phenotype representation platforms. We also evaluated well-known diagnostic criteria and clinical decision-making guidelines to encompass a broader category of algorithms.Results We propose 10 desired characteristics for a flexible, computable PheRM: (1) structure clinical data into queryable forms; (2) recommend use of a common data model, but also support customization for the variability and availability of EHR data among sites; (3) support both human-readable and computable representations of phenotype algorithms; (4) implement set operations and relational algebra for modeling phenotype algorithms; (5) represent phenotype criteria with structured rules; (6) support defining temporal relations between events; (7) use standardized terminologies and ontologies, and facilitate reuse of value sets; (8) define representations for text searching and natural language processing; (9) provide interfaces for external software algorithms; and (10) maintain backward compatibility.Conclusion A computable PheRM is needed for true phenotype portability and reliability across different EHR products and healthcare systems. These desiderata are a guide to inform the establishment and evolution of EHR phenotype algorithm authoring platforms and languages.